Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Intracameral moxifloxacin use in cataract surgery to prevent endophthalmitis

Poster Details

First Author: S. Cetinkaya TURKEY

Co Author(s):    Y. Cetinkaya   N. Acir   Z. Dadaci              

Abstract Details


To evaluate the safety and efficacy of intracameral moxifloxacin in preventing endophthalmitis after cataract surgery.


Turkish Red Crescent Hospital, Konya, Turkey


Sixty-five eyes of 65 patients underwent cataract surgery between January and June 2012. Some patients received intracameral moxifloxacin at the end of surgery, while others did not (controls). Pre- and postperative logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA), intraocular pressure (IOP), corneal edema, and anterior chamber (AC) status were examined.


Preoperative BCVA was approximately 20/130 in both groups. After surgery, moxifloxacin and control patients had a BCVA of 20/25 and 20/23, respectively (p = 0.160). Preoperative IOP was 14.93 ± 2.77 mmHg (range: 11–21 mmHg) in moxifloxacin patients and 15.06 ± 2.42 mmHg (range: 12–21 mmHg) in controls (P = 0.850). After surgery, IOP was not statistically different between two groups (moxifloxacin: 14.06 ± 2.31 [range: 10–19 mmHg], controls: 14.03 ± 2.36 mmHg [range: 10–19 mmHg], P = 0.960). Slight differences in corneal edema (P = 0.623) and anterior chamber cell (P = 0.726) incidences between two groups were not statistically significant.


Intracameral moxifloxacin is safe and effective in preventing endophtalmitis after cataract surgery.

Financial Disclosure:


Back to Poster listing